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Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is a common and often fatal malignancy. Immunochemotherapy, a
combination of rituximab to standard chemotherapy, has resulted in improved survival. However a substantial proportion of
patients still fail to reach sustained remission. We have previously demonstrated that autocrine brain-derived neurotrophic
factor (BDNF) production plays a function in human B cell survival, at least partly via sortilin expression. As neurotrophin
receptor (Trks) signaling involved activation of survival pathways that are inhibited by rituximab, we speculated that
neurotrophins may provide additional support for tumour cell survival and therapeutic resistance in DLBCL.
Methodology/Principal Findings: In the present study, we used two DLBCL cell lines, SUDHL4 and SUDHL6, known to be
respectively less and more sensitive to rituximab. We found by RT-PCR, western blotting, cytometry and confocal
microscopy that both cell lines expressed, in normal culture conditions, BDNF and to a lesser extent NGF, as well as
truncated TrkB and p75
NTR/sortilin death neurotrophin receptors. Furthermore, BDNF secretion was detected in cell
supernatants. NGF and BDNF production and Trk receptor expression, including TrkA, are regulated by apoptotic conditions
(serum deprivation or rituximab exposure). Indeed, we show for the first time that rituximab exposure of DLBCL cell lines
induces NGF secretion and that differences in rituximab sensitivity are associated with differential expression patterns of
neurotrophins and their receptors (TrkA). Finally, these cells are sensitive to the Trk-inhibitor, K252a, as shown by the
induction of apoptosis. Furthermore, K252a exhibits additive cytotoxic effects with rituximab.
Conclusions/Significance: Collectively, these data strongly suggest that a neurotrophin axis, such NGF/TrkA pathway, may
contribute to malignant cell survival and rituximab resistance in DLBCL.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
type of non-Hodgkin’s lymphoma (NHL). This lymphoma is a
clinically and biologically heterogeneous disease [1]. Rituximab (a
chimeric anti-CD20 monoclonal antibody), alone or combined
with chemotherapy, has demonstrated efficacy in DLBCL,
resulting in an increased proportion of cured patients disease
[2]. The in vivo mechanisms of rituximab-mediated antitumor
effects include antibody-dependent cellular cytotoxicity (ADCC),
complement-dependent cell cytotoxicity (CDC), growth-inhibition
and apoptosis by binding to the CD20 antigen specifically
expressed on B-cells [3]. Constitutively activated growth signaling
pathways have frequently been observed in DLBCL tumors and
DLBCl cell lines including protein kinase AKT and nuclear factor
kB (NF-kB) transcription factor. Activation of these pathways
controls a variety of mechanisms that inhibit apoptosis and
prolong cell survival notably in resulting downstream overexpres-
sion of functional anti-apoptotic proteins such as Bcl-xL and Bcl-2
that can also lead to chemoresistance [4,5]. Interestingly, by
contrast, treatment with rituximab inhibits these survival pathways
resulting in augmentation of the association of Bcl-XL and Bad, as
well as downregulation of Bcl-XL expression leading to chemo-
sensitization [6]. Despite therapeutic advances, a subset of patients
does not respond or relapses after the initial treatment, and the
mechanism of rituximab resistance, a growing concern, is not clear
[3]. Thus, it is still important to identify new targets for
development of additional therapeutic options.
Members of the neurotrophin (NT) family like nerve growth
factor (NGF) and brain-derived neurotrophic factor (BDNF) are
structurally and functionally related neurotrophic factors that
control neuron survival and axon growth during nervous system
development and repair [7]. Each NT binds to a specific high-
affinity tyrosine kinase receptor, Trk. NGF binds to TrkA, BDNF
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27213and NT-4/5 to TrkB. In addition NTs share a common low-
affinity p75 NT receptor (p75
NTR) a member of the tumor necrosis
factor (TNF) receptor superfamily. Signaling by NTs through Trk
and p75
NTR receptors has been extensively studied in the context
of nervous system development, survival, and plasticity. NT
binding to Trk receptors results in receptor dimerization, leading
to subsequent signaling cascades including MAPK (mitogen-
activated protein kinase), PI3K/Akt (phosphatidylinositol-3 ki-
nase/Akt) and NF-kB that favour cellular survival [8,9]. In
contrast, the functions of the p75
NTR receptor are complex and
have been more difficult to ascertain. It is clear that p75
NTR
functions as a Trk co-receptor that increases binding affinity and
specificity of Trk [10], but engagement of p75
NTR also triggers
divergent pathways involving notably Jun kinase (JNK) activity
and caspase activation, that facilitate apoptosis [11]. Thus, while
p75
NTR binding can increase the survival effect of Trk-NT
interactions, p75
NTR can also induce apoptosis when Trk is
reduced or absent. Furthermore, NTs are synthesized as pro-NTs
which proteolysis generates mature NTs. Both the pro-NTs and
the mature forms are secreted. However they display opposite
biological activities on cell proliferation and apoptosis. Indeed,
pro-NTs such as pro-NGF and pro-BDNF, display greater affinity
for p75
NTR and preferentially interact with sortilin —also known
as neurotensin receptor-3 and a member of the Vps10p-domain
receptor family —together with p75
NTR to form a complex
capable of activating an apoptotic cascade [12,13]. Thus, the
overall cellular outcome in response to NT exposure reflects a
balance between p75
NTR and Trk engagement that is controlled
by pro-NT processing.
Although NTs are thought to exert their actions predominantly
on neurons, increasing evidence shows that some NTs, notably
NGF and BDNF, can also influence the development and
activation of many cell types of the immune system, including B
lymphocytes [14,15,16]. NT (NGF, BDNF) and TrkA, TrkB,
p75
NTR receptor expressions have been detected in normal human
B lymphocytes and in human B cell lines. Membranous or
intracellular localization varied according to cell line and culture
conditions [17,18]. In B cells, autocrine BDNF and NGF signaling
appears to be essential for the survival of mature and memory B
cells, respectively, especially in pro-apoptotic or pro-inflammatory
conditions [19,20,21]. Trk and their NT ligands have been also
found in malignant B cell lines notably multiple myeloma and
NHL cell lines [22,23] but involvement of NTs in the pathogeny of
B cell tumors, and notably in DLBCL, needs to be elucidated.
In recent studies we have shown an autocrine production of
BDNF and pro-BDNF in human pre-B, mature, and plasmacytic
malignant B cell lines. The endogenous BDNF released under
stress culture conditions, such as serum deprivation and/or Fas-
induced apoptosis, exerts antiapoptotic effects. Furthermore, we
demonstrated that this autocrine regulation is linked to the
presence of sortilin which has not been previously described in B
cells [24]. The goal of this study was to define the NGF and BDNF
expression and secretion and their respective TrkA, TrkB and
p75
NTR receptors in DLBCL cells cultured under standard and
apoptotic conditions, including exposure to rituximab, to evaluate
a potential link between rituximab sensitivity and NT production.
To assess this hypothesis we used two DLBCL cell lines, SUDHL4
and SUDHL6, known to be respectively less and more sensitive to
the rituximab induced-apoptosis [25]. We report herein i) that
NGF, BDNF, TrkB, p75
NTR and its co-receptor sortilin were
expressed in two DLBCL cell lines and ii) that their responsiveness
to rituximab was depending on NT secretion and TrkA expression
suggesting a relationship between Trk signaling and rituximab
sensitivity.
Materials and Methods
Human B cell lines and cell cultures
The CD20-expressing human DLBCL cell lines SUDHL4 and
SUDHL6 were obtained from DSMZ (Braunschweig, Germany).
Under basal culture conditions, the B cell lines (5610
5 cells/ml)
were cultured in RPMI 1640 medium (Gibco, Grand Island, NY,
USA) supplemented with 10% heat-inactivated Fetal Calf Serum
(FCS), 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-
glutamine (Gibco) at 37uC in a humidified atmosphere containing
5% CO2. NTs production and expression of p75
NTR and Trk
receptors were analyzed in different cell culture conditions (24–
72 h): with (control) and without FCS (serum deprivation), in the
presence of 1–20 mg/ml of rituximab (MabTheraH, stock 10 mg/
ml, a generous gift from CHRU Dupuytren of Limoges, Pharmacie
centrale, France) or control human IgG (Jackson ImmunoResearch
Europe Ltd., Newmarket, UK). For K-252a sensitivity tests, cells
were grown in triplicate in 96 well tissue culture plates (starting with
5610
4 cells/well) with various concentrations of K-252a (0–
500 nM, Alomone labs, Jerusalem, Israel).
Antibodies
Rabbit mAb anti-Akt (Akt[pan], C67E7), anti-phospho-Akt
(Ser473, D9E and Thr308, C31E5E), and rabbit mAb anti-b-actin
(13E5) were obtained from Cell Signaling Technology (Beverly,
MA, USA). Mouse mAbs Anti-TrkA (MAB1751) and anti-TrkB
(MAB3971) were purchased from R&D System (Minneapolis,
MN, USA). Anti-NGF (rabbit polyclonal Ab, H-20), anti-BDNF
(rabbit polyclonal Ab, N-20), anti-p75
NTR (H-137, a rabbit
polyclonal Ab reactive with the N-terminal domain of p75
NTR),
anti-p75
NTR (H-92, a rabbit polyclonal Ab reactive with the C-
terminal domain of p75
NTR) and anti-sortilin (a goat polyclonal
Ab, C20) antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Purified mouse or rabbit IgG Ab
(Sigma Aldrich, Saint Louis, MO, USA) were used as negative
controls to determine background and positive thresholds.
Cell viability assay
Cellular viability of DLBCL cell lines was assessed using the
colorimetric XTT (sodium 39-[1-(phenylaminocarbonyl)-3,4-tetra-
zolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate)-
assay (Cell Proliferation Xit II, XTT Roche, Meylan, France)
according to the manufacturer’s instructions. Results are expressed
as the relative cell viability of untreated control cells.
Analysis of apoptosis
DNA fragmentation was detected by flow cytometric analysis
after propidium iodide staining as previously described [26] and
using a FACSVantage DIVA SE flow cytometer. Percentage of
apoptotic cells was then defined as the percentage of cells with
DNA staining before G0/G1 peak (hypodiploid, sub-G1 peak).
Furthermore apoptosis-associated phosphatidylserine (PS) expo-
sure on the outer plasma membrane was also analyzed by flow
cytometry using the PI/Annexin V-FITC double staining method
(kit Beckman Coulter, Villepinte, France); this method effectively
distinguishes apoptotic cells from necrotic cells. Annexin V-
positive and propidium iodide-negative cells were scored as
apoptotic cells. Cells were analyzed with a FACSCalibur flow
cytometer (Becton Dickinson, Heidelberg, Germany) acquiring
10 000 events.
Flow cytometric analysis
Expression of TrkA, TrkB, p75
NTR, BDNF and NGF was
studied on 2610
6 cells by flow cytometry with or without (TrkA,
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NTR) permeabilization (Intrastain Kit, DakoCyto-
mation, Glostrup, Denmark) as per the manufacturer’s instruc-
tions. After washing in 1% BSA-PBS and incubation with 5%
BSA-PBS for 15 min at room temperature, cells were incubated at
room temperature for 15 min with either anti-TrkA or anti-TrkB
(12.5 mg/ml) or anti-p75
NTR, anti-BDNF, anti-NGF (10 mg/ml) or
isotypic controls. After washing, samples were then incubated with
Alexafluor 488-conjugated goat either anti-mouse IgG Ab or anti-
rabbit IgG Ab (both, 1 mg/ml; Invitrogen, Cergy Pontoise, France)
for 15 min at room temperature. After washing, cells were
suspended in PBS and analyzed with a FACSCalibur flow
cytometer (Becton Dickinson). For samples without permeabiliza-
tion (membrane expression of receptors), all incubations were
realized for 30 min at 4uC and finally resuspended in PBS with
1% formaldehyde, before analysis by flow cytometry acquiring
10 000 events.
Immunofluorescence microscopy
After two washes in PBS, samples (2–4610
6 cells) were fixed for
30 min at 4uC with 1% formaldehyde in PBS for 10 min at 4uC.
After washing, an ice-cold 100% methanol permeabilization step
was realized for 10 minutes at 4uC and then cells were rinsed in
PBS for 5 min. The samples were further blocked with 5% goat
serum in PBS and then incubated for 30 minutes at 4uC with
primary antibodies (anti-Trk, anti-BDNF, anti-NGF, p75
NTR)o r
IgG controls. After washing, cells were incubated with Alexafluor-
conjugated secondary antibodies (dilution: 1/1000) for 30 min at
4uC. After two step washes, samples were finally incubated with
DAPI (Molecular Probes, Invitrogen), coverslipped and sealed
using mounting media (Dako North America, Carpinteria, CA,
USA). Pictures were captured using a Leica microscope and a
Leica digital camera. Images were processed using Leica IM500
Image Manager. For cell surface antigen stainings, incubations
with primary and secondary antibodies were realized before the
formaldehyde fixation step.
Western blotting
Proteins were obtained from whole cell lysates or from
supernatants of cell cultures. After two washes in PBS, cell lysates
were prepared using lysis buffer (20 mM Tris–HCl [pH 7.5], 1%
Nonidet P40, 10% glycerol, 150 mM NaCl supplemented with
1% protease and phosphatase inhibitor mixtures) (Sigma) followed
by centrifugation at 20 000 g for 20 min at 4uC. Cell supernatants
were concentrated to analyze neurotrophins released by B cultured
cells. Briefly, growth medium was collected and centrifuged for
30 min at 3000 g in vivaspin columns (Millipore, Billerica, MA,
USA). Equal amounts of proteins from cell lysates and cell
supernatants (50 mg/lane) were separated on SDS-polyacrylamide
gels under denaturing conditions and transferred onto nitrocellu-
lose sheets (PALL Gelman Laboratory, Ann Arborn, MI, USA).
Nonspecific binding sites were blocked for 1 h with 5% nonfat dry
milk in TBS containing 0.1% Tween 20. After overnight
incubation at 4uC with specific primary Ab (dilution 1/200),
membranes were incubated with appropriate HRP-conjugated
secondary Ab (DakoCytomation; dilution 1/1000) for 1 h at room
temperature and revealed by an enhanced chemiluminescent
detection method (Immubilon Western, Millipore). Protein-
loading control was performed with anti-bactin Ab. Western blots
were scanned using a bioimaging system (Genesnap; Syngene
Europe, Cambridge, UK).
For co-immunoprecipitation studies, cell lysates (200 mg) were
incubated with anti-Akt or anti-BDNF antibody (1/50) for 1 h at
4uC and then with protein A/G-Agarose beads (Santa Cruz
Biotechnology) with gentle mixing overnight at 4uC. Beads were
washed three times with lysis buffer and subsequently boiled for
5 min in SDS-sample buffer and finally immunoprecipitates were
subjected to SDS-polyacrylamide gel electrophoresis, before
analysis by western blotting.
Measurement of neurotrophin secretion by ELISA
BDNF and NGF concentrations in cell supernatants were
determined by using the BDNF Emax and NGF Emax Immuno-
Assay Systems (Promega France, Charbonnie `res les Bains, France)
as previously described [24]. This assay cannot distinguish
between pro-NT and mature NT. When detected, neurotrophin
secretions were expressed as pg/10
6 cells.
RT-PCR analysis
TRIzol was used to isolate total RNA from 5610
6 SUDHL
cells. cDNA synthesis was performed with the Super Script III
First-strand synthesis kit (Invitrogen) according to the manufac-
turer’s instructions, using oligo(dT). Then amplification was
performed using TaqDNA polymerase (Invitrogen) and specific
primer sequences (Table 1) as previously reported [24]. Tran-
scripts of NGF, BDNF, TrkA, TrkB, p75
NTR and sortilin were
obtained using UnoCycler (VWR France, Fontenay sous Bois,
France). Total RNA isolated from a human neuroblastoma cell
line (IMR32) was used as a positive control.
Statistical analysis
Data on cell viability were compared by ANOVA with Statview
5.0 software (Abacus Concepts). A value of p#0.05 was considered
as significant.
Results
Expression and production of NTs in DLBCL cell lines
BDNF and NGF expression in DLBCL cell lines was char-
acterized at the transcript level in the both cell lines SUDHL4 and
SUDHL6, maintained in basal (10% FCS) culture conditions for 3
days (Figure 1A). Controls assessed that cell viability was not
modified at 72 h in both SHDHL cell lines (data not shown).
These expressions were confirmed at the protein level by western
blotting with the detection for BDNF and, to a lesser extent for
NGF, of the immature forms of NTs (pro-NGF: 27 kDa, pro-
BDNF: a 32/34 kDa doublet proteins, Figure 1B). Moreover NT
expression was also confirmed by flow cytometric analysis after
cell permeabilization in four experiments. Indeed, as shown in
Figure 1C, NGF and BDNF were detected in the majority of cells
under basal culture conditions (80.4%613.8% and 87.3%6
5.6% of positive cells, respectively, for SUDHL4 and 77.6%6
12.7% and 82.7%616.8% of positive cells, respectively, for
SUDHL6). Interestingly, pro-BDNF and mature BDNF were also
found in culture supernatants from both cell lines, notably in
SUDHL6 cell supernatants, after immunoprecipitation and
western blotting (Figure 1D), whereas this basal production was
often under the range of detection of the ELISA assay (data not
shown). Moreover, secretion of NGF in basal culture conditions of
SUDHL cell lines was not detected by immunoprecipitation nor
by ELISA (data not shown).
DLBCL cell lines express p75
NTR/sortilin and TrkB
receptors
To evaluate the possibility of an autocrine mechanism of NT
signaling we also analyzed Trk and p75
NTR expression in the two
DLBCL cell lines using RT-PCR, western-blotting and flow
cytometry. Transcripts of the low-affinity common receptor
Neurotrophins and DLBCL Rituximab Sensitivity
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NTR, and strikingly its co-receptor sortilin were detected by
RT-PCR in both cell lines (Figure 2A) which was confirmed at the
protein level by western blotting (Figure 2B) and immunofluores-
cence (p75
NTR, data not shown). However, membrane expression
of p75
NTR was not detected by flow cytometry (data not shown).
As shown in Figure 2A, after 72 h cell culture in basal conditions
we never detected TrkA mRNA in either cell line. Interestingly,
RT-PCR analyses revealed, in both cell lines and notably in
Table 1. Primers used in RT-PCR studies.
Name Primer sequences Amplified fragments Hybridation temperature 39 location
BDNF F: TACTTTGGTTGCATGAAGGCTGCC 266 pb 58uC5 9 6
R: ACTTGACTACTGAGCATCACCCTG
NGF F: ATACAGGCGGAACCACACTC 313 pb 58uC1 2 3
R: TGCTCCTGTGAGTCCTGTTG
TrkA F: TCAACAAATGTGGACGGAGA 197 pb 58uC1 3 7 2
R: GTGGTGAACACAGGCATCAC
TrkB145 F: AGGGCAACCCGCCCACGGAA 571 pb 60uC2 8 6 0
R: GGATCGGTCTGGGGAAAAG
TrkB95 F: GTTTCATAAGATCCCACTGGA 261 pb 58uC7 1 1 1
R: TGCTGCTTAGCTGCCTGAGAG
p75
NTR F: GTGGGACAGAGTCTGGGTGT 200 pb 60uC3 1 0 9
R: AAGGAGGGGAGGTGATAGGA
Sortilin F: CTGGGTTTGGCACAATCTTT 199 pb 60uC1 1 6 1
R: CACCTTCCTCCTTGGTCAAA
b-actin F: TGGATTCCTGTGGCATCCATGAAAC 355 pb 58–60uC2 8 2 8
R: TAAAACGCAGCTCAGTAACAGTCCG
F: forward; R: reverse.
doi:10.1371/journal.pone.0027213.t001
Figure 1. DLBCL cell lines produce neurotrophins. A: RT-PCR detection of NGF and BDNF mRNA was performed on SUDHL4 and SUDHL6 cells
cultured with 10% FCS for 72 h. b-actin was included as a control of cDNA quality. B: Neurotrophin production was confirmed by western blotting of
cell lysates demonstrating immature forms. Blots were reprobed with anti- b-actin as a loading control. C: Flow cytometry analysis demonstrating
NGF (bold line) and BDNF intracellular expression in permeabilized cells (isotypic controls in dotted line). D: secretion of immature and mature BDNF
was also detected in cell supernatants after immunoprecipitation (IP) and immunoblotting (IB) analysis. The neuroblastoma cell line, IMR32, was used
as a positive control. Data are from one representative experiment out of four (RT-PCR, Flow cytometry and WB) or two (IP/WB) performed.
doi:10.1371/journal.pone.0027213.g001
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(Figure 2A) but not full-length TrkB (gp145, data not shown).
However, as for p75
NTR, we could not detect by flow cytometry
membranous TrkA or TrkB protein expression in SUDHL4 cells
cultured in basal conditions. In contrast, as shown in Figure 2C,
flow cytometric analyses from 4 separate experiments revealed
intracellular staining of TrkB in the majority of cells for both
DLBCL cell lines, butTrkB membrane detection was observed only
for ,20% SUDHL6 cells (17%67% of positive cells). According
that anti-TrkB antibodies were raised to recognize the extracellular
domain of both isoforms of the receptor (gp95 and gp145), our
results collectively suggest that the TrkB receptor expressed in
SUDHL6 cells is the truncated TrkB. Finally, positive expression of
TrkB by some SUDHL6 was also confirmed by immunofluores-
cence assays (Figure 2D), whereas isotype control antibodies did not
produce any detectable staining of the cells (data not shown). Of
note,this TrkBexpression bySUDHL6wasobserved incells,which
were also positive for BDNF staining, suggesting a potential
autocrine support for BDNF/TrkB signaling pathway (Figure 2D).
Modulation of NT production and TrkB/p75
NTR
expressions are induced by serum deprivation
As membranous expression of TrkB and p75
NTR was moderate
or not present respectively in basal conditions, we further analyzed
these expressions and NT production under stress conditions.
Thus, cells were studied after serum deprivation for 24–72 h.
Results were obtained after 72 h serum deprivation only for
SUDHL4 cells, which were more resistant to this apoptotic
condition. The apoptotic response was evaluated by flow
cytometric detection of DNA fragmentation (27%63% of sub-
G1 cells in deprived condition, as compared to 3%63% in the
10% FCS control, data not shown). Under such conditions, we
observed a strong reduction in the number of NGF and BDNF
positive SUDHL4 cells surviving after 72 h in culture (Figure 3E).
Consistent with these data, production of BDNF in cell
supernatant was no longer detectable after immunoprecipitation
and western blotting (Figure 3D). Strikingly, after 72 h culture in
FCS-free medium, mRNA TrkB truncated expression was clearly
enhanced (Figure 3A) as compared with basal conditions (10%
FCS), which was confirmed at the protein level by flow cytometry
(Figure 3E). Indeed, in contrast to basal conditions, TrkB mem-
branous expression appeared in 30%610% SUDHL4 deprived
cells after 72 h culture, whereas intracellular detection of TrkB
was strongly reduced, suggesting membrane relocation of this
receptor. Finally a weak enhanced expression of protein p75
NTR
was also observed by western-blotting in serum deprived cell
lysates, without affecting sortilin expression or association
(Figure 3B and C). Of note, the bands of p75
NTR were detected
Figure 2. DLBCL cell lines express neurotrophin receptors. A: RT-PCR detection of p75
NTR, and its co-receptor sortilin, TrkA and truncated
gp95TrkB mRNA was performed on SUDHL cells cultured with 10% FCS for 72 h. b-actin was included as a control of cDNA quality. B: The truncated
TrkB, p75
NTR and sortilin receptor protein expression was confirmed by western blotting of cell lysates. Blots were reprobed with anti- b-actin as a
loading control. C: Flow cytometry analysis demonstrating TrkB membrane detection expressed in percentage of positive cells (bold line) in
unpermeabilized SUDHL6 cells in contrast to SUDHL4 cells, whereas both cell lines expressed intracellular TrkB (dotted line: the isotypic controls). D:
Immunofluorescence staining was performed, as described in Materials and Methods, in DLBCL cell lines that confirmed surface TrkB expression (in
green) in some BDNF (inset in red) positive SUDHL6 cells (in blue: DAPI staining). The neuroblastoma cell line, IMR32, was used as a positive control.
Data are representative of four independent experiments.
doi:10.1371/journal.pone.0027213.g002
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ing to the mature and the ectodomain shedding pieces of p75
NTR
respectively. Collectively, our results showed lower neurotrophin
production and enhanced expression of receptors (i.e. p75
NTR,
truncated TrkB) in association with apoptotic culture conditions.
Rituximab sensitivity of DLBCL cell lines is associated
with regulation of NT production and Trk receptor
expression
The CD20-expressing human DLBCL cell lines tested in the
present study has been reported to have differential apoptotic
sensitivity in response to rituximab, SUDHL6 cells being more
sensitive than other DLBCL cell lines and notably SUDHL4. Thus
to evaluate a potential link between anti-CD20 sensitivity and NT
production, we analyzed secretion of NGF and BDNF, as well as
expression of receptors in cell cultures with or without rituximab.
As a negative control, an isotype control of rituximab was also
done (IC). To investigate the dose-response relationship and the
kinetics of growth inhibition and cell death induced by rituximab,
SUDHL cells were incubated in the presence of various
concentrations of rituximab (0, 0.1, 1, 10 and 20 mg/ml) for 6 to
72 h. Cell viability was then monitored by the XTT assay.
Furthermore, the ability of rituximab to induce apoptosis in
SUDHL cells was measured by detecting PS translocation using
Annexin V/PI staining, and evaluation of DNA fragmentation,
followed by flow cytometry analyses. Figure 4 shows results
obtained (viability) or representative (annexin V/PI stainings) of 4
independent experiments. Viability and PS translocation data
confirmed the apoptotic effect of rituximab on both DLBCL cell
lines, with a dose-dependent and a kinetic effect. No significant
difference was observed when the isotypic control was compared
to the culture control without rituximab (Figure 4A). Furthermore,
Figure 3. Modulation of neurotrophin and TrkB expression by SHDHL4 cells is induced by serum deprivation. A: RT-PCR analysis of
NGF, BDNF, TrkA, gp95TrkB, p75
NTR and sortilin mRNA on SUDHL4 cells submitted to 72 h serum deprivation (2FCS) as compared to standard culture
conditions (10% FCS, +FCS). b-actin was included as a control of cDNA quality. B: Western blott detection of truncated TrkB and p75
NTR protein
expression. Blots were reprobed with anti- b-actin as a loading control. C: Immunoprecipitation of sortilin (IP) and western blotting analysis (IB,
immunoblotting with anti-p75
NTR or anti-sortilin as control) demonstrating the association of sortilin with p75
NTR in cell lysates of both culture
conditions. D: secretion of BDNF detected in cell supernatants after immunoprecipitation and western blotting. E: Flow cytometry analysis
demonstrating membranous expression of TrkB (bold line) and intracellular TrkB, NGF (bold line) and BDNF expressions expressed in percentage of
SUDHL4 positive cells cultured with or without FCS (dotted line: isotypic controls). Data are representative of four independent experiments.
doi:10.1371/journal.pone.0027213.g003
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showed a significant reduction of viability, which was seen for both
cell lines from 1 mg/ml rituximab and after 48 h treatment (i.e. at
1 mg/ml rituximab: p,0.01 and p,0.05 for SUDHL4 and
SUDHL6 respectively). This effect was enhanced after 72 h of
cell exposure (p,0.001 for both cell lines and from 1 mg/ml
rituximab). However, the percent of hypodiploid nuclei (sub-G1)
induced by rituximab in the two cell lines was relatively low, even
if a pronounced effect was found with SUDHL6 (data not shown).
The maximum response was reached for SUDHL4 at 20 mg/ml
rituximab after 72 h (Figure 4A). In contrast, SUDHL6 cells were
more sensitive, with a strong cell cytotoxicity following 24 h
exposure to rituximab, which was observed even at low dose of
rituximab (p=0.05 for 0.1 and 1 mg/ml rituximab treatment of
Figure 4. Effects of rituximab treatment on DLBCL cells lines. A: Viability of SUDHL4 and SUDHL6 cells exposed to various concentrations of
rituximab (RTX) during 72 h in serum basal culture condition (10% FCS). Viability was determined by XTT assay and calculated relative to time-
matched untreated (0) controls. A control human IgG was also used as negative control (IC: Isotype control). Results are expressed as means 6 SD of
four experiments. B: Apoptosis induced by rituximab was measured after 24 h culture by Annexin-V-FITC/PI dual staining and the ratio of apoptotic
(lower right quadrant) and necrotic (upper right quadrant) cells expressed as cell percentages was analyzed by flow cytometry. C: Rituximab induced
inhibition of PI3K/Akt signaling which was detected by immunoprecipitation of Akt and western blott analysis of phosphorylated Akt (P-Akt) at 48 h
and 72 h in SUDHL6 and SUDHL4 cell lysates. Data are representative of four independent experiments.
doi:10.1371/journal.pone.0027213.g004
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SUDHL4 cell line). This differential apoptotic sensitivity of the
two cell lines in response to rituximab was confirmed by flow
cytometric analysis. A dose response was obtained for SUDHL4
after 24 h exposure, whereas a strong apoptotic response was often
observed in SUDHL6 at this time for lower doses of rituximab (i.e.
61% of apoptotic cells as shown in Figure 4B), following by a
decrease with high concentrations. Consistent with this, constitu-
tive phosphorylation of Akt seemed to be enhanced in the more
rituximab-resistant cell line, SUDHL4. Moreover, inhibition of the
constitutively active PI3K/Akt signaling pathway was observed in
SUDHL6 cells previously than SUDHL4 cells. Indeed, in contrast
to the weak inhibition of P-Akt (Ser473) observed in SUDHL4, a
strong dephosphorylation of Akt (Ser473 and Thr308) by
rituximab was detected in SUDHL6 cell lysates after 48 h
exposure to 20 mg/ml rituximab (Figure 4C). As results for NTs
strongly suggested an autocrine/paracrine survival axis in the
SUDHL cell lines tested, we next analyzed expression of NTs and
their receptors in cell cultures after 48 and 72 h exposure to
rituximab (20 mg/ml). We found that rituximab induced NGF
expression in both cell lines (Figure 5B), which was associated with
the detection of NGF in cell supernatants. In contrast to basal
culture conditions, strong NGF secretion was detected by ELISA
for both cell lines after 48 h rituximab exposure that further
decreased at 72 h (Figure 5D). In SUDHL4, the less rituximab
sensitive cell line, it is noteworthy that NGF secretion was
correlated with TrkA receptor expression, although weak, both at
the transcript and protein levels, in contrast to SUDHL6 cells.
Indeed, a low level of TrkA mRNA was detected after 48 h
(SUDHL4 and SUDHL6 cells) and 72 h (SUDHL4 cells) of
Figure 5. Effects of rituximab on neurotrophin production and Trk expression in DLBCL cells lines. A: RT-PCR analysis of NGF, BDNF,
TrkA, truncated TrkB, sortilin and p75
NTR mRNA in SUDHL4 and SUDHL6 after 48 h and 72 h exposition to 20 mg/ml rituximab (RTX). b-actin was
included as a control of cDNA quality. B: Western blott demonstrating in particular NGF protein expression following rituximab treatment and
heterodimerization of p75
NTR with sortilin in cell lysates. Blots were reprobed with anti- b-actin as a loading control. C: Enhanced TrkA expression
induced by rituximab was observed for the less rituximab sensitive cell line, SUDHL4, after immunoprecipitation (IP) and immunoblotting (IB) with
specific antibodies. D: NGF production was confirmed after rituximab exposure by detection with ELISA in cell supernatants of both cell lines,
whereas it was undetectable (ND, non detected) in control cultures. Results are means 6 SD of three independent experiments. E: BDNF secretion
seemed to decrease in the most rituximab sensitive cell line, SUDHL6, as shown by western blott analysis of BDNF in cell lysate immunoprecipitates.
Data are from one representative experiment out of four (RT-PCR, WB) or two (IP/WB) performed.
doi:10.1371/journal.pone.0027213.g005
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TrkA receptor at the protein level was only observed for SUDHL4
cells by immunoprecipitation of TrkA in cell lysates (Figure 5C).
As shown in Figure 5A,TrkA mRNA were also slightly detected
after 48 h of culture in the control cell of both cell lines.
Furthermore, we observed a decreased production of BDNF and
pro-BDNF in cell supernatants of the most rituximab sensitive cell
line, SUDHL6, exposed to rituximab, in contrast to SUDHL4
cells which seemed to maintain BDNF synthesis (Figure 5E).
Moreover, rituximab did not modify expression of the truncated
form of TrkB (gp95), or p75
NTR or sortilin expression at both
mRNA and protein levels (Figure 5 A and B). Similarly, there was
no change in protein expression of the p75
NTR forms (75 and
50 kDa) found in sortilin immunoprecipitates in both cell line
lysates. Thus, these data suggest that differences in rituximab-
induced apoptoptic sensitivity could involve differential expression
of survival Trk signaling in DLBCL cell lines.
Pharmacologic inhibition of Trk receptors induces
apoptosis of DLBCL cells
Presence of both Trk receptors and NTs, notably BDNF
expressed with TrkB receptors, in both cell lines suggest an
autocrine pathway of neurotrophin signaling in DLBCL. In order
to address the functionality of Trk receptors expressed in DLBCL
cell lines, SUDHL cells were incubated with various concentra-
tions of the Trk inhibitor K252a and cell survival was measured
(Figure 6A). Results showed a strongest sensitivity of SUDHL4
cells to K252a by 24 h treatment, with significant decrease of
viability correlated with increasing amounts of K252a. Indeed,
SUDHL6 cells were significantly sensitive to cell death after 48 h
of K252a exposure (data not shown). As shown in Figure 6B,
K252a-induced cytotoxicity in SUDHL4 cells was associated with
a strong apoptosis, measured with annexin-V/PI staining, after a
48 h exposure (i.e. 30.8% of apoptotic cells with 350 nM K252a vs
13% in DMSO culture controls). Interestingly, apoptosis obtained
in SUDHL4 cells by inhibiting Trk receptors was comparable to
the apoptotic effect of rituximab (i.e. 36.9% of apoptotic cells for
20 mg/ml rituximab). Furthermore, K252a exhibited additive
cytotoxic effects with rituximab (i.e. 56.7% of apoptotic cells in
presence of rituximab 20 mg/ml+K252a 350 nM). These data
strongly support our hypothesis that autocrine neurotrophin
signaling is an important survival factor for DLBCL cell lines,
and may interfere with rituximab leading to therapeutic
resistances.
Discussion
In the present study we demonstrated that DLBCL cell lines
expressed the gene transcripts and proteins for BDNF and to a
lesser extent NGF, and the high-affinity truncated TrkB as well
low-affinity p75
NTR receptors. Furthermore, secretion of BDNF
and pro-BDNF were also observed in DLBCL cell line super-
natants, even though variable with the cell line. Moreover, in both
cell lines, we detected strong sortilin (NTR3) expression, an
intracellular transport protein for NTs and proNTs which is also
involved, by heterodimerization with p75
NTR, in the cell death
effect of pro-NTs. However, they lacked, in basal culture
conditions, detectable mRNA expression for the full-length TrkB
and TrkA receptors, but expressed the truncated form of TrkB.
NT production and Trk receptor expression, including TrkA,
seemed to be regulated by culture conditions that modulate cell
survival (serum deprivation or rituximab exposure).
Several microarray studies performed on untreated de novo
DLBCL identified two main prognostically different subgroups.
Both were characterized by a distinct gene expression profile
either characteristic of normal germinal center B-cells or activated
blood memory B-cells. The germinal center B-cell-like (GCB)
subgroup was correlated with a significantly better prognosis in
comparison to the activated B-cell-like (ABC) subgroup [27,28].
mRNA for NGF and BDNF were recently detected in ABC (OCI-
LY3) and GCB (OCI-LY19) DLBCL cell lines, but NT protein
production was undetectable by ELISA [23]. In the present study
we used two GCB DLBCL cell lines (SUDHL4 and SUDHL6)
[27,29]. We confirmed previous data and further demonstrated for
the first time that NT secretion (BDNF) can be observed in cell
supernatants after basal culture conditions (10% FCS). Of note,
BDNF production was associated with a strong cytoplasmic TrkB
sequestration suggesting, as was demonstrated in B cell lines [24],
a potential survival autocrine signaling pathway. On the other
hand, as shown by coimmunoprecipitation and western blotting
analyses, association of sortilin with the death receptor p75
NTR
was also observed, for the first time in DLBCL cells, in the present
study. Moreover, we detected also the ectodomain shedding pieces
(50 kDa) of p75
NTR in the sortilin immunoprecipitates. These data
suggest proteolytic processing of p75
NTR and thus release of the
intracellular domain of the receptor that is known to occur after
ligand activation, initiating a second signaling apoptosis step [30].
Proteolytic processing of p75
NTR, together with strong intracyto-
plasmic sequestration of the receptor, may explain our difficulties
in membrane detection of this receptor by flow cytometry. Indeed,
the anti-p75
NTR used for this analysis was selected for its ability to
target the extracellular domain of human p75
NTR. Present data
demonstrated that pro-NTs, and notably pro-BDNF, are pro-
duced by both DLBCL cell lines tested. As the heterodimeric
receptor p75
NTR/sortilin is known to be required for the cell death
effect of pro-BDNF [13,31], pro-BDNF-p75
NTR/sortilin signaling
pathway may act, in the absence or low membrane TrkB
expression, by sensitizing cells to apoptotic cell death.
We detected expression of the truncated form of TrkB (gp95)
but not full-length, in both DLBCL cell lines. Of note, the
prominent form of truncated TrkB mRNA was previously
reported in normal B lymphocytes [24]. The putative function
of these truncated TrkB receptors, lacking tyrosine kinase activity,
is still not clear. However, they can exert a functional activity in
neurons, allowing activation and proliferation of neuroblasts in the
presence of BDNF [32,33]. Moreover, in the present study,
gp95TrkB expression increased in DLBCL cell line (SUDHL4)
under stress conditions (i.e. serum deprivation), with a membrane
relocation of the receptor as for previous B cell lines [24]. In
contrast to TrkB, the heterodimeric p75
NTR/sortilin death recep-
tor seemed to be unaffected by serum deprivation. This TrkB
receptor relocation may suggest an autocrine survival mechanism
of neurotrophin signaling in deprived cells, as we recently demon-
strated in colorectal cancer cells [34]. However, we also observed a
strong decrease in BDNF production in association with apoptosis
which argues for a potential survival function of BDNF. Phar-
macological inhibition of Trk receptors (K252a, 200 nM) was
recently shown to inhibit proliferation and survival of malignant B
cells, including an ABC DLBCL cell line (OCI-LY3) whereas the
truncated TrkB receptor was the major Trk receptor expressed by
these cells [23]. But an apoptotic effect of K252a was not observed
on the GCB cell line tested (OCI-LY19). In the present study, we
showed a differential response of the two GCB cell lines used.
Whereas K252a significantly decreases the cell viability in DHL4
cells, it did not alter the viability of DHL6 cells at least after 24 h
drug exposure, while cytotoxic effect was only observed by 48 h
and for higher drug concentrations (500 nM, data not shown).
Such differences in data can be explained by variations in the Trk
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presence of TrkB transcripts in both cell lines, TrkA mRNA was
also detected in the previous report of Sniderhan et al. [23] for
OCI-LY3 cells and not for OCI-LY19 cells suggesting potential
TrkA and TrkB protein expression in the ABC cell line as
compared to GCB. In our study, albeit we did not detect TrkA
protein expression in basal culture conditions in both cell lines, we
had observed a low level of TrkA mRNA after 48 h standard
culture conditions, suggesting a possible regulation of TrkA
expression by the cell cycle. Although K-252a affects several
other kinases at higher concentrations and the effects observed
may thus not only be due to inhibition of Trk signaling [35],
numerous studies have used nanomolar quantities of K252a as a
selective inhibitor of NT signaling. Thus, our present data strongly
support the notion that SUDHL cells express functional Trk
receptors.
Figure 6. Pharmacologic inhibition of Trk receptors inhibits survival of DLBCL cell lines and synergizes rituximab induced
apoptosis. A: Cell viability was evaluated using the XTT test for both SUDHL cell lines cultured for 24 h in presence of various concentrations of
K252a. Data are expressed as means 6 SD of the relative cell viability of untreated control cells obtained from three independent experiments.
Significant p values (*: p,0.05 and **: p,0.01) were determined in comparison with 100 nM K252a. B: K252a (350 nM) induced apoptosis in SUDHL4
cells, demonstrating a synergistic effect with rituximab (0–20 mg/ml) exposure. Example of flow cytometry analysis of apoptosis using Annexin-V-FITC
and propidium iodide (PI), as detailed in legend of Figure 4, obtained after 48 h cell culture. Data are from one representative experiment out of three
performed.
doi:10.1371/journal.pone.0027213.g006
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concern, is not entirely clear. Several tumor-associated and host-
associated mechanisms have been proposed, including mutations
or poor surface CD20 antigen expression and, more recently,
polymorphisms in FccRIIIA receptor [36]. To further assess the
role of NT production in rituximab sensitivity, we exposed cells to
rituximab, as the two studied SUDHL cell lines have been
reported to have differential apoptotic sensitivity in response to
rituximab [26]. As expected, apoptosis induced by rituximab was
observed in both cell lines and associated with an inhibition of the
constitutively activated PI3K-Akt signaling pathway, known to
lead to chemosensitization [5,37]. Furthermore, we confirmed the
higher apoptotic sensitivity of SUDHL6 [26]. Such differential
sensitivity to apoptosis may be explained by the lower constitu-
tively expression of P-Akt detected in SUDHL6 cells as compared
to SUDHL4, in accordance to previous observations for other
DLBCL cell lines [5]. Indeed, we did not find a significant
difference in CD20 expression between the two cells lines (data not
shown), as was previously reported [38]. Strikingly, we demon-
strated for the first time that NGF production and secretion in cell
supernatants were induced by rituximab exposure in both cell lines
SUDHL4 and SUDHL6, by contrast to the weak NGF expression
detected in basal culture conditions. Furthermore, up-regulation of
TrkA expression was observed after 48 h exposure to rituximab in
SUDHL4 cells, and not in the more sensitive cell line SUDHL6.
In addition, rituximab-induced apoptosis was concomitantly
associated with a decreased of BDNF secretion in SUDHL6 cell
supernatants. These results argue for a relationship between
rituximab resistance and an autocrine NT survival loop through
Trk receptor signaling of survival pathways, inhibited by
rituximab. This hypothesis was supported by pharmacologic Trk
inhibition (K252a) that enhanced rituximab-induced apoptosis of
SUDHL cells. While exposure of SUDHL4 cells to K252a alone
resulted in apoptotic cell death comparable to the effect induced
by rituximab, the combination of both was synergistic in the
apoptotic response of the more resistant DLBCL cell line. These
data suggest that a NT/Trk fine-tuning regulation may be of
crucial important in drug sensitivity/cell survival in DLBCL.
However, mechanisms underlying these differential regulations of
NT/Trk expression induced by rituximab in SUDHL cells
remains to be clarified.
In conclusion, therapeutic targeting of Trk-neurotrophin axis is
beginning to emerge for NHL and present results point out to this
possibility in DLBCL. We demonstrated notably that secretion of
NGF, BDNF and the expression of their survival Trk receptors are
regulated in DLBCL cell lines by culture conditions, and
potentially could contribute to malignant cell survival and
rituximab resistance.
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